[go: up one dir, main page]

PH12015500795A1 - N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors - Google Patents

N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors

Info

Publication number
PH12015500795A1
PH12015500795A1 PH12015500795A PH12015500795A PH12015500795A1 PH 12015500795 A1 PH12015500795 A1 PH 12015500795A1 PH 12015500795 A PH12015500795 A PH 12015500795A PH 12015500795 A PH12015500795 A PH 12015500795A PH 12015500795 A1 PH12015500795 A1 PH 12015500795A1
Authority
PH
Philippines
Prior art keywords
inhibitors
ethyl
cyclic amine
benzamide derivatives
compounds
Prior art date
Application number
PH12015500795A
Other versions
PH12015500795B1 (en
Inventor
Kilburn John Paul
Rasmussen Lars Kyhn
Jessing Mikkel
Eldemenky Eman Mohammed
Chen Bin
Jiang Yu
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49546380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015500795(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PH12015500795A1 publication Critical patent/PH12015500795A1/en
Publication of PH12015500795B1 publication Critical patent/PH12015500795B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention is directed to N-(2-(cyclic amine)ethyl)benzamide derivatives of formula (I), as P2X7 inhibitors, pharmaceutical compositions comprising said compounds and uses of the compounds to treat pain, inflammation, neurological disorders, or neuropsychiatric disorders.
PH12015500795A 2012-10-12 2015-04-10 N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors PH12015500795B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713099P 2012-10-12 2012-10-12
PCT/EP2013/071253 WO2014057080A2 (en) 2012-10-12 2013-10-11 Cyclic amines

Publications (2)

Publication Number Publication Date
PH12015500795A1 true PH12015500795A1 (en) 2015-06-08
PH12015500795B1 PH12015500795B1 (en) 2015-06-08

Family

ID=49546380

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12015500795A PH12015500795B1 (en) 2012-10-12 2015-04-10 N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
PH12017500351A PH12017500351A1 (en) 2012-10-12 2017-02-27 N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12017500351A PH12017500351A1 (en) 2012-10-12 2017-02-27 N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors

Country Status (29)

Country Link
US (6) US9108938B2 (en)
EP (2) EP2906549B1 (en)
JP (2) JP6333827B2 (en)
KR (1) KR20150067189A (en)
CN (1) CN104955819B (en)
AP (1) AP2015008407A0 (en)
AR (1) AR092975A1 (en)
AU (1) AU2013328586B2 (en)
BR (1) BR112015008123A2 (en)
CA (1) CA2886559A1 (en)
CL (1) CL2015000879A1 (en)
CR (1) CR20150184A (en)
DO (1) DOP2015000078A (en)
EA (1) EA201590669A1 (en)
EC (1) ECSP15014177A (en)
HK (1) HK1213880A1 (en)
IL (1) IL238011A0 (en)
MA (1) MA37989A1 (en)
MX (1) MX2015004414A (en)
NI (1) NI201500052A (en)
NZ (1) NZ630816A (en)
PE (1) PE20150638A1 (en)
PH (2) PH12015500795B1 (en)
RU (1) RU2015116112A (en)
SG (1) SG11201502684YA (en)
TN (1) TN2015000114A1 (en)
TW (1) TW201427947A (en)
WO (1) WO2014057080A2 (en)
ZA (1) ZA201503246B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201427947A (en) * 2012-10-12 2014-07-16 Lundbeck & Co As H Cyclic amines
TWI598325B (en) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 Benzoamide
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
KR102232744B1 (en) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Indole carboxamide derivatives as p2x7 receptor antagonists
KR102222220B1 (en) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Heterocyclic amide derivatives as p2x7 receptor antagonists
KR102220847B1 (en) 2013-01-22 2021-02-26 이도르시아 파마슈티컬스 리미티드 Heterocyclic amide derivatives as p2x7 receptor antagonists
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445707A1 (en) 1962-05-05 1969-03-13 Hoechst Ag Piperidine compounds and processes for their preparation
US3435038A (en) 1965-06-01 1969-03-25 Sandoz Ag 5,6,7,9,10,14b-hexahydroisoquinolo (2,1-d) benzo (1,4) diazepines
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
SE9904738D0 (en) * 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
SE0003476D0 (en) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
DE60229646D1 (en) 2001-07-17 2008-12-11 Organon Nv N- (1-DIMETHYLAMINOCYCLOALKYL) METHYL BENZAMID DERIVATIVES
TW200300083A (en) 2001-11-12 2003-05-16 Pfizer Prod Inc Benzamide, heteroarylamide and reverse amides
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
WO2004099146A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
EP1500651A1 (en) 2003-07-25 2005-01-26 Bayer CropScience S.A. N-[2-(2-Pyridinyl)ethyl]benzamide compounds and their use as fungicides
WO2005013914A2 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
TWI368482B (en) 2003-12-19 2012-07-21 Bayer Sas New 2-pyridinylethylbenzamide derivatives
WO2005094514A2 (en) 2004-03-24 2005-10-13 Merck & Co., Inc. Heteroaryl piperidine glycine transporter inhibitors
WO2006008191A1 (en) 2004-07-23 2006-01-26 Bayer Cropscience Sa 3-pyridinylethylbenzamide derivatives as fungicides
AU2005317846B2 (en) 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
PE20061156A1 (en) 2004-12-23 2006-12-16 Glaxo Group Ltd BENZAMIDE DERIVATIVES AS INHIBITING AGENTS OF THE GLYCINE TRANSPORTER
ES2536351T3 (en) * 2005-06-13 2015-05-22 Merck Sharp & Dohme Limited Therapeutic agents
RU2008119412A (en) 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-Phenyl-Phenylacetamide Non-Nucleoside Inhibitors of Reverse Transcriptase
JP2009057282A (en) 2005-12-19 2009-03-19 Astellas Pharma Inc Carboxylic acid derivative or salt thereof
TWI435863B (en) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd N-2-(hetero) arylethylcarboxamide derivative and pest controlling
RU2010103102A (en) 2007-07-02 2011-08-10 Зингента Партисипейшнс Аг (Ch) NEW MICROBIOCIDES
ITMC20070152A1 (en) 2007-07-26 2009-01-27 Faggiolati Pumps Spa SUBMERSIBLE MIXER IN PARTICULAR SUBMERSIBLE MIXER FOR WASTE WATER TREATMENT TANKS.
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8431704B2 (en) * 2008-04-22 2013-04-30 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
ES2345527B1 (en) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona KV 1.3 CHANNEL BLOCKING SUBSTANCES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HYPERPLASIA OF THE INTIMATE.
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
UA114287C2 (en) 2011-03-02 2017-05-25 Дзе Юніверсіті Оф Токіо MEANS TO CONTROL ENDOPARASITES
PH12014500977A1 (en) 2011-11-02 2014-06-09 Bayer Ip Gmbh Compounds with nematicidal activity
TW201427947A (en) 2012-10-12 2014-07-16 Lundbeck & Co As H Cyclic amines
TWI598325B (en) 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 Benzoamide

Also Published As

Publication number Publication date
AU2013328586A1 (en) 2015-04-16
WO2014057080A2 (en) 2014-04-17
WO2014057080A3 (en) 2014-07-10
MX2015004414A (en) 2015-06-24
EP2906549A2 (en) 2015-08-19
SG11201502684YA (en) 2015-05-28
EP3536689A1 (en) 2019-09-11
US20190307766A1 (en) 2019-10-10
ZA201503246B (en) 2016-11-30
HK1213880A1 (en) 2016-07-15
NI201500052A (en) 2016-02-16
US9108938B2 (en) 2015-08-18
BR112015008123A2 (en) 2017-07-04
JP6333827B2 (en) 2018-05-30
US10124010B2 (en) 2018-11-13
US20180177793A1 (en) 2018-06-28
NZ630816A (en) 2017-03-31
CL2015000879A1 (en) 2015-11-06
PH12017500351A1 (en) 2017-12-11
US9593105B2 (en) 2017-03-14
TN2015000114A1 (en) 2016-06-29
MA37989A1 (en) 2016-02-29
US20170008898A1 (en) 2017-01-12
TW201427947A (en) 2014-07-16
EP2906549B1 (en) 2019-04-17
RU2015116112A (en) 2016-12-10
EA201590669A1 (en) 2015-10-30
JP2018140995A (en) 2018-09-13
AU2013328586B2 (en) 2017-07-13
US20170128460A1 (en) 2017-05-11
AR092975A1 (en) 2015-05-13
ECSP15014177A (en) 2015-12-31
US20140107335A1 (en) 2014-04-17
KR20150067189A (en) 2015-06-17
CR20150184A (en) 2015-07-21
PE20150638A1 (en) 2015-05-13
CN104955819A (en) 2015-09-30
IL238011A0 (en) 2015-05-31
CA2886559A1 (en) 2014-04-17
PH12015500795B1 (en) 2015-06-08
US20150306114A1 (en) 2015-10-29
DOP2015000078A (en) 2015-09-15
JP2015533143A (en) 2015-11-19
US9415055B2 (en) 2016-08-16
US9861639B2 (en) 2018-01-09
AP2015008407A0 (en) 2015-04-30
CN104955819B (en) 2018-06-19

Similar Documents

Publication Publication Date Title
PH12017500351A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
EA201591727A1 (en) BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS
CY1121625T1 (en) PRMT5 INHIBITORS AND USES THEREOF
NZ750187A (en) Pyridone amides as modulators of sodium channels
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201400161A1 (en) SUBSTITUTED HETEROAROMATIC PYRAZOL-CONTAINING CARBOXAMIDE AND UTERIN DERIVATIVES AS VIANILLOID RECEPTOR LIGANDS
BR112015018284A2 (en) amides as sodium channel modulators
EA201690598A1 (en) AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS
MX368833B (en) Quinoline and quinazoline amides as modulators of sodium channels.
EA201691121A1 (en) HYDROXYAMIDE COMPOUNDS OF Pyrimidine As Inhibitors of Protein Deacetylases and Methods for Their Use
NZ630830A (en) Benzamides
EA201591360A1 (en) AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS
EA201790599A1 (en) COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS
BR112015029495A2 (en) heterocyclic compounds as hedgehog signaling pathway inhibitors
MY174747A (en) Bace1 inhibitors
EA201890331A1 (en) PYRIDINODICARBOXAMIDES FOR APPLICATION AS BROMODOUM INHIBITORS AS
EA201400822A1 (en) DERIVATIVES OF HETEROCYCLIC AMIDES AS AN ANTAGONISTS OF P2HRECEPTOR
MX2015000903A (en) Carbamate/urea derivatives.
EA201600323A1 (en) DERIVATIVES OF PIPERAZINE AND THEIR APPLICATION AS A MEDICINE
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.
IN2014KN00849A (en)
IN2014KN00847A (en)
TN2013000179A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists